Concept

Riluzole

Riluzole is a medication used to treat amyotrophic lateral sclerosis and other motor neuron diseases. Riluzole delays the onset of ventilator-dependence or tracheostomy in some people and may increase survival by two to three months. Riluzole is available in tablet and liquid form. Riluzole was approved in the United States for the treatment of ALS by the U.S. Food and Drug Administration (FDA) in 1995. A Cochrane Library review states a 9% gain in the probability of surviving one year. Very common (>10% frequency): nausea; weakness; decreased lung function Common (1–10% frequency): headache; dizziness; drowsiness; vomiting; abdominal pain; increased aminotransferases Uncommon (0.1-1% frequency): pancreatitis; interstitial lung disease Rare (

Official source

https://en.wikipedia.org/wiki/Riluzole

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (3)

Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model

TDP-43 pathology is a hallmark of Amyotrophic Lateral Sclerosis (ALS), yet no therapeutic strategy effectively targets its upstream molecular consequences. Here, we investigated whether the anti-TDP-43 intrabody scFv B1 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model, and whether these effects translate into functional benefit after symptom onset. Using phage display, we previously identified single-chain variable fragments (scFvs) binding TDP-43, including the candidate therap

2026

Compartmentalized Microfluidics for In Vitro Alzheimer’s Disease Studies

Philippe Renaud

Compartmentalized microfluidic devices are designed to engineer the cellular environment for cell cultures. The practical use of the compartmentalized chambers can be expanded to induce co-pathological cell cultures, where one cell population expresses a specific disease state, while being in direct-cell or metabolic contact to a second or third unaffected cell population. A typical example for co-pathological cell states in the brain is the well-known neurodegenerative Alzheimer’s disease (AD), which still

Springer New York2015

Immunoisolated cell implants for intracerebral delivery of anti-Aß single chain Fv antibodies in the APP23 Alzheimer's mouse model

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in the elderly population. AD currently affects approximately 27 million people worldwide. A pathological hallmark of AD is the accumulation and deposition of the amyloid beta (Aβ) pe ...

EPFL2009

Related concepts (1)

Parkinson's disease

Parkinson's disease (PD), or simply Parkinson's, is a chronic degenerative disorder of the central nervous system that affects both the motor system and non-motor systems. The symptoms usually emerge slowly, and as the disease worsens, non-motor symptoms become more common. Early symptoms are tremor, rigidity, slowness of movement, and difficulty with walking. Problems may also arise with cognition, behaviour, sleep, and sensory systems. Parkinson's disease dementia becomes common in advanced stages of the disease.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Official source

https://en.wikipedia.org/wiki/Riluzole

About this result

Related publications (3)

Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model

2026

Compartmentalized Microfluidics for In Vitro Alzheimer’s Disease Studies

Philippe Renaud

Springer New York2015

Immunoisolated cell implants for intracerebral delivery of anti-Aß single chain Fv antibodies in the APP23 Alzheimer's mouse model

EPFL2009

Related people (1)

Pierre Magistretti

Pierre J. Magistretti is an internationally-recognized neuroscientist who has made significant contributions in the field of brain energy metabolism. His group has discovered some of the cellular and molecular mechanisms that underlie the coupling between neuronal activity and energy consumption by the brain. This work has considerable ramifications for the understanding of the origin of the signals detected with the current functional brain imaging techniques used in neurological and psychiatric research (see for example Magistretti et al, Science, 283: 496 497, 1999). He is the author of over 100 articles published in peer-reviewed journals. He has given over 80 invited lectures at international meetings or at universities in Europe and North America, including the 2000 Talairach Lecture at the Functional Mapping of the Human Brain Conference. In November 2000 he has been a Mc Donnel Visiting Scholar at Washington University School of Medicine. Pierre J. Magistretti is the President-Elect (2002 2004) of the Federation of European Neuroscience Societies (FENS) which has a membership of over 15000 European neuroscientists. He has been first president of the Swiss Society for Neuroscience (1997-1999) and the first Chairman of the Department of Neurosciences of the University of Lausanne (1996 1998). Pierre J. Magistretti is Professor of Physiology (since 1988) at the University of Lausanne Medical School. He has been Vice-Dean of the University of Lausanne Medical School from 1996 to 2000. Pierre Magistretti, is Director of the Brain Mind Institute at EPFL and Director of the Center for Psychiatric Neuroscience of the University of Lausanne and CHUV. He is also Director of the NCCR SYNAPSY "the synaptic bases of mental diseases". POSITIONS AND HONORS MAIN POSITION HELD 1988-2004 Professor of Physiology, University of Lausanne Medical School 1996-2000 Vice-Dean for Preclinical Departments, University of Lausanne Medical School 2001-2004 Chairman, Department of Physiology, University of Lausanne Medical School 2004-present Professor and Director, Center for Psychiatric Neuroscience, Department of Psychiatry, University of Lausanne Medical School and Hospitals (UNIL-CHUV) (Joint appointment with EPFL) 2005-2008 Professor and Co-Director, Brain Mind Institute, Federal Institute of Technology (EPFL), Lausanne (Joint appointment with UNIL-CHUV) 2007-present Chairman of the Scientific Advisory Board of Centre dImagerie Biomédicale (CIBM), an Imaging Consortium of the Universities, University Hospitals of Lausanne and Geneva and of Ecole Polytechnique Fédérale de Lausanne 2008-present Professor and Director, Brain Mind Institute, Federal Institute of Technology (EPFL), Lausanne Joint appointment with UNIL-CHUV) 2010-present Director, National Center for Competence in Research (NCCR) The synaptic bases of mental diseases of the Swiss National Science Foundation 2010-present Secretary General, International Brain Research Organization (IBRO) MAIN HONORS AND AWARDS 1997 Recipient of the Theodore-Ott Prize of the Swiss Academy of Medical Sciences 2001 Elected Member of Academia Europaea 2001 Elected Member of the Swiss Academy of Medical Sciences, ad personam 2002 Recipient of the Emil Kraepelin Guest Professorship, Max Planck Institute für Psychiatry, Münich 2006 Elected Professor at Collège de France, Paris, International Chair 2007-2008 2009 Goethe Award for Psychoanalytic Scholarship, Canadian Psychological Association 2011 Camillo Golgi Medal Award, Golgi Fondation 2011 Elected Member of the American College of NeuroPsychopharmacology (ACNP)

Related concepts (1)

Parkinson's disease

Related people (1)

Pierre Magistretti